{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:25:30Z","timestamp":1783607130861,"version":"3.55.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","bmn.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.molmed.2024.07.008","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T12:14:31Z","timestamp":1723810471000},"page":"181-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Emerging therapies in hereditary ataxias"],"prefix":"10.1016","volume":"31","author":[{"given":"Mallory L.S.","family":"Eisel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Ashizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8052-9240","authenticated-orcid":false,"given":"Sub H.","family":"Subramony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2024.07.008_bb0005","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1474-4422(23)00068-6","article-title":"Autosomal dominant cerebellar ataxias: new genes and progress towards treatments","volume":"22","author":"Coarelli","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.molmed.2024.07.008_bb0010","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s00415-022-11383-6","article-title":"The inherited cerebellar ataxias: an update","volume":"270","author":"Coarelli","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.molmed.2024.07.008_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104931","article-title":"Clinical and genetic keys to cerebellar ataxia due to FGF14 GAA expansions","volume":"99","author":"Mereaux","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.molmed.2024.07.008_bb0020","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1007\/s00415-022-11192-x","article-title":"Screening for RFC-1 pathological expansion in late-onset ataxias: a contribution to the differential diagnosis","volume":"269","author":"Barghigiani","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.molmed.2024.07.008_bb0025","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1056\/NEJMra1006610","article-title":"The autosomal recessive cerebellar ataxias","volume":"366","author":"Anheim","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2024.07.008_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104606","article-title":"Friedreich ataxia \u2013 pathogenesis and implications for therapies","volume":"132","author":"Delatycki","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.molmed.2024.07.008_bb0035","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000200149","article-title":"RFC1 repeat distribution in the Cypriot population: study of a large cohort of patients with undiagnosed ataxia and non-disease controls","volume":"10","author":"Votsi","year":"2024","journal-title":"Neurol. Genet."},{"key":"10.1016\/j.molmed.2024.07.008_bb0040","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2217\/nmt-2022-0011","article-title":"Friedreich ataxia: clinical features and new developments","volume":"12","author":"Keita","year":"2022","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.molmed.2024.07.008_bb0045","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1007\/s00415-023-12118-x","article-title":"Frataxin analysis using triple quadrupole mass spectrometry: application to a large heterogeneous clinical cohort","volume":"271","author":"Lynch","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.molmed.2024.07.008_bb0050","doi-asserted-by":"crossref","DOI":"10.1042\/NS20200093","article-title":"Mitochondrial and metabolic dysfunction in Friedreich ataxia: update on pathophysiological relevance and clinical interventions","volume":"5","author":"Lynch","year":"2021","journal-title":"Neuronal Signal."},{"key":"10.1016\/j.molmed.2024.07.008_bb0055","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ana.24248","article-title":"Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial","volume":"76","author":"Pandolfo","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2024.07.008_bb0060","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/jnc.12322","article-title":"Co-enzyme Q10 and idebenone use in Friedreich\u2019s ataxia","volume":"126","author":"Parkinson","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.molmed.2024.07.008_bb0065","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.molmed.2023.12.002","article-title":"Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia","volume":"30","author":"Pilotto","year":"2024","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.molmed.2024.07.008_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004253","article-title":"Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia","volume":"4","author":"Paupe","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2024.07.008_bb0075","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1089\/ars.2012.4537","article-title":"Frataxin deficiency leads to defects in expression of antioxidants and Nrf2 expression in dorsal root ganglia of the Friedreich\u2019s ataxia YG8R mouse model","volume":"19","author":"Shan","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.molmed.2024.07.008_bb0080","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fncel.2018.00188","article-title":"Novel Nrf2-inducer prevents mitochondrial defects and oxidative stress in Friedreich\u2019s ataxia models","volume":"12","author":"Abeti","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.molmed.2024.07.008_bb0085","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ana.25934","article-title":"Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe Study)","volume":"89","author":"Lynch","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2024.07.008_bb0090","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.29286","article-title":"Efficacy of omaveloxolone in Friedreich\u2019s ataxia: delayed-start analysis of the MOXIe Extension","volume":"38","author":"Lynch","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.molmed.2024.07.008_bb0095","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/acn3.51897","article-title":"Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data","volume":"11","author":"Lynch","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.molmed.2024.07.008_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217776","article-title":"Dimethyl fumarate dosing in humans increases frataxin expression: a potential therapy for Friedreich\u2019s ataxia","volume":"14","author":"Jasoliya","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2024.07.008_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1260977","article-title":"Rationale and protocol of a double-blind, randomized, placebo-controlled trial to test the efficacy, safety, and tolerability of dimethyl fumarate in Friedreich ataxia (DMF-FA-201)","volume":"17","author":"Pane","year":"2023","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.molmed.2024.07.008_bb0110","article-title":"Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2024.07.008_bb0115","doi-asserted-by":"crossref","first-page":"14568","DOI":"10.1038\/s41598-019-49870-y","article-title":"Induced pluripotent stem cells-derived neurons from patients with Friedreich ataxia exhibit differential sensitivity to resveratrol and nicotinamide","volume":"9","author":"Georges","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2024.07.008_bb0120","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1007\/s00415-015-7719-2","article-title":"An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels","volume":"262","author":"Yiu","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.molmed.2024.07.008_bb0125","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000200034","article-title":"Efficacy and safety of leriglitazone in patients with Friedreich ataxia: a phase 2 double-blind, randomized controlled trial (FRAMES)","volume":"8","author":"Pandolfo","year":"2022","journal-title":"Neurol. Genet."},{"key":"10.1016\/j.molmed.2024.07.008_bb0130","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s00415-022-11501-4","article-title":"Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia","volume":"270","author":"Lynch","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.molmed.2024.07.008_bb0135","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ana.24260","article-title":"Epigenetic therapy for Friedreich ataxia","volume":"76","author":"Soragni","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2024.07.008_bb0140","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1126\/science.aan6414","article-title":"Synthetic transcription elongation factors license transcription across repressive chromatin","volume":"358","author":"Erwin","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.molmed.2024.07.008_bb0145","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/hmg\/ddr554","article-title":"A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich\u2019s ataxia mouse model","volume":"21","author":"Vyas","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2024.07.008_bb0150","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/acn3.51971","article-title":"Safety, pharmacokinetics, and pharmacodynamics of nomlabofusp (CTI-1601) in Friedreich\u2019s ataxia","volume":"11","author":"Clayton","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.molmed.2024.07.008_bb0155","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jconrel.2023.01.067","article-title":"AAV vectors applied to the treatment of CNS disorders: clinical status and challenges","volume":"355","author":"Kang","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.molmed.2024.07.008_bb0160","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.3390\/ijms22041815","article-title":"Future prospects of gene therapy for Friedreich\u2019s ataxia","volume":"22","author":"Ocana-Santero","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2024.07.008_bb0165","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1038\/s41596-023-00875-y","article-title":"Structure-guided AAV capsid evolution strategies for enhanced CNS gene delivery","volume":"18","author":"Gonzalez","year":"2023","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.molmed.2024.07.008_bb0170","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1089\/hum.2020.264","article-title":"Central nervous system therapeutic targets in Friedreich ataxia","volume":"D31","author":"Harding","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2024.07.008_bb0175","article-title":"Perspectives of the Friedreich ataxia community on gene therapy clinical trials","volume":"32","author":"Trantham","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.molmed.2024.07.008_bb0180","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1089\/hum.2023.088","article-title":"How great a risk do you take? A qualitative study exploring attitudes of individuals with Friedreich ataxia toward gene therapy","volume":"34","author":"Lieschke","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2024.07.008_bb0185","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.molmed.2021.09.007","article-title":"Delivery of therapeutic AAV9 vectors via cisterna magna to treat neurological disorders","volume":"28","author":"Marchi","year":"2022","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.molmed.2024.07.008_bb0190","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ymthe.2019.11.012","article-title":"A safe and reliable technique for CNS delivery of AAV vectors in the cisterna magna","volume":"28","author":"Taghian","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2024.07.008_bb0195","article-title":"Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies","volume":"2020","author":"Bailey","year":"1739","journal-title":"Brain Res."},{"key":"10.1016\/j.molmed.2024.07.008_bb0200","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.omtm.2020.04.012","article-title":"Translational feasibility of lumbar puncture for intrathecal AAV administration","volume":"17","author":"Hinderer","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.molmed.2024.07.008_bb0205","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/hum.2017.026","article-title":"Evaluation of intrathecal routes of administration for adeno-associated viral vectors in large animals","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2024.07.008_bb0210","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.omtm.2018.12.001","article-title":"Kinetics and MR-based monitoring of AAV9 vector delivery into cerebrospinal fluid of nonhuman primates","volume":"13","author":"Ohno","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.molmed.2024.07.008_bb0215","first-page":"1095","article-title":"Positron emission tomography quantitative assessment of off-target whole-body biodistribution of I-124-labeled adeno-associated virus capsids administered to cerebral spinal fluid","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2024.07.008_bb0220","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2024.07.008_bb0225","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/brainsci10020119","article-title":"Management of neuroinflammatory responses to AAV-mediated gene therapies for neurodegenerative diseases","volume":"10","author":"Perez","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/j.molmed.2024.07.008_bb0230","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nm.3510","article-title":"Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich\u2019s ataxia","volume":"20","author":"Perdomini","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2024.07.008_bb0235","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/hmg\/ddy427","article-title":"Correction of half the cardiomyocytes fully rescue Friedreich ataxia mitochondrial cardiomyopathy through cell-autonomous mechanisms","volume":"28","author":"Belbellaa","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2024.07.008_bb0240","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.ymthe.2018.05.006","article-title":"Rapid and complete reversal of sensory ataxia by gene therapy in a novel model of Friedreich ataxia","volume":"26","author":"Piguet","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2024.07.008_bb0245","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1089\/hum.2019.363","article-title":"Stress-induced mouse model of the cardiac manifestations of Friedreich\u2019s ataxia corrected by AAV-mediated gene therapy","volume":"31","author":"Salami","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2024.07.008_bb0250","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.omtm.2020.08.018","article-title":"High levels of frataxin overexpression lead to mitochondrial and cardiac toxicity in mouse models","volume":"19","author":"Belbellaa","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.molmed.2024.07.008_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101193","article-title":"AAV8 gene therapy reverses cardiac pathology and prevents early mortality in a mouse model of Friedreich\u2019s ataxia","volume":"32","author":"Chang","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.molmed.2024.07.008_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2022.903139","article-title":"Advantages and limitations of gene therapy and gene editing for Friedreich\u2019s ataxia","volume":"4","author":"Sivakumar","year":"2022","journal-title":"Front. Genome Ed."},{"key":"10.1016\/j.molmed.2024.07.008_bb0265","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/nat.2017.0703","article-title":"Activation of frataxin protein expression by antisense oligonucleotides targeting the mutant expanded repeat","volume":"28","author":"Li","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.molmed.2024.07.008_bb0270","doi-asserted-by":"crossref","first-page":"11560","DOI":"10.1093\/nar\/gkab954","article-title":"Targeting 3\u2032 and 5\u2032 untranslated regions with antisense oligonucleotides to stabilize frataxin mRNA and increase protein expression","volume":"49","author":"Li","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.molmed.2024.07.008_bb0275","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000358801","article-title":"The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies","volume":"42","author":"Ruano","year":"2014","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.molmed.2024.07.008_bb0280","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1504","article-title":"Spinocerebellar ataxia 27B: a novel, frequent and potentially treatable ataxia","volume":"14","author":"Pellerin","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.molmed.2024.07.008_bb0285","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S1474-4422(10)70183-6","article-title":"Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond","volume":"9","author":"Durr","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.molmed.2024.07.008_bb0290","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaneurol.2019.0423","article-title":"Prevalence of carriers of intermediate and pathological polyglutamine disease-associated alleles among large population-based cohorts","volume":"76","author":"Gardiner","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.molmed.2024.07.008_bb0295","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1073\/pnas.0400615101","article-title":"Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors","volume":"101","author":"Tsai","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2024.07.008_bb0300","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/jnc.16010","article-title":"From the disruption of RNA metabolism to the targeting of RNA-binding proteins: the case of polyglutamine spinocerebellar ataxias","volume":"168","author":"Moreira-Gomes","year":"2024","journal-title":"J Neurochem"},{"key":"10.1016\/j.molmed.2024.07.008_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104635","article-title":"Pathogenesis of SCA3 and implications for other polyglutamine diseases","volume":"134","author":"McLoughlin","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.molmed.2024.07.008_bb0310","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/hmg\/ddh139","article-title":"Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes","volume":"13","author":"Helmlinger","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2024.07.008_bb0315","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41580-021-00382-6","article-title":"Molecular mechanisms underlying nucleotide repeat expansion disorders","volume":"22","author":"Malik","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.molmed.2024.07.008_bb0320","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.202300114","article-title":"Polyglutamine disease proteins: commonalities and differences in interaction profiles and pathological effects","volume":"24","author":"Bonsor","year":"2024","journal-title":"Proteomics"},{"key":"10.1016\/j.molmed.2024.07.008_bb0325","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.23","article-title":"siRNA versus miRNA as therapeutics for gene silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.molmed.2024.07.008_bb0330","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/ijms25010146","article-title":"Advances in nucleic acid research: exploring the potential of oligonucleotides for therapeutic applications and biological studies","volume":"25","author":"Moccia","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2024.07.008_bb0335","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.molmed.2024.07.008_bb0340","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","article-title":"Antisense oligonucleotide therapies for neurodegenerative diseases","volume":"42","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.molmed.2024.07.008_bb0345","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4062\/biomolther.2023.001","article-title":"Drug discovery perspectives of antisense oligonucleotides","volume":"31","author":"Kim","year":"2023","journal-title":"Biomol. Ther. (Seoul)"},{"key":"10.1016\/j.molmed.2024.07.008_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095362","article-title":"RNA interference-based therapy for spinocerebellar ataxia type 7 retinal degeneration","volume":"9","author":"Ramachandran","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2024.07.008_bb0355","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/mt.2013.279","article-title":"Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy","volume":"22","author":"Keiser","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2024.07.008_bb0360","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/ana.24789","article-title":"RNAi prevents and reverses phenotypes induced by mutant human ataxin-1","volume":"80","author":"Keiser","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2024.07.008_bb0365","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1038\/mt.2013.144","article-title":"Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease","volume":"21","author":"Costa Mdo","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2024.07.008_bb0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003341","article-title":"Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease","volume":"3","author":"Alves","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2024.07.008_bb0375","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/mt.2014.108","article-title":"Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7","volume":"22","author":"Ramachandran","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2024.07.008_bb0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052396","article-title":"Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice","volume":"8","author":"Nobrega","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2024.07.008_bb0385","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/mt.2013.152","article-title":"Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice","volume":"21","author":"Rodriguez-Lebron","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2024.07.008_bb0390","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.ymthe.2017.01.021","article-title":"Unravelling endogenous microRNA system dysfunction as a new pathophysiological mechanism in Machado-Joseph disease","volume":"25","author":"Carmona","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2024.07.008_bb0395","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/nm1076","article-title":"RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia","volume":"10","author":"Xia","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2024.07.008_bb0400","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.biomaterials.2015.12.021","article-title":"Intravenous administration of brain-targeted stable nucleic acid lipid particles alleviates Machado-Joseph disease neurological phenotype","volume":"82","author":"Conceicao","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.molmed.2024.07.008_bb0405","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf5660","article-title":"An miRNA-mediated therapy for SCA6 blocks IRES-driven translation of the CACNA1A second cistron","volume":"8","author":"Miyazaki","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2024.07.008_bb0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100086","article-title":"RNA interference mitigates motor and neuropathological deficits in a cerebellar mouse model of Machado-Joseph disease","volume":"9","author":"Nobrega","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2024.07.008_bb0415","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.3390\/ijms25084354","article-title":"AAV-mediated CAG-targeting selectively reduces polyglutamine-expanded protein and attenuates disease phenotypes in a spinocerebellar ataxia mouse model","volume":"25","author":"Niewiadomska-Cimicka","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2024.07.008_bb0420","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/ana.26713","article-title":"Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice","volume":"94","author":"McLoughlin","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2024.07.008_bb0425","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.omtn.2019.07.004","article-title":"Suppression of mutant protein expression in SCA3 and SCA1 mice using a CAG repeat-targeting antisense oligonucleotide","volume":"17","author":"Kourkouta","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.molmed.2024.07.008_bb0430","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aap8677","article-title":"Antisense oligonucleotides targeting mutant ataxin-7 restore visual function in a mouse model of spinocerebellar ataxia type 7","volume":"10","author":"Niu","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2024.07.008_bb0435","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature22044","article-title":"Antisense oligonucleotide therapy for spinocerebellar ataxia type 2","volume":"544","author":"Scoles","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2024.07.008_bb0440","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/ana.26713","article-title":"Antisense oligonucleotide silencing reverses abnormal neurochemistry in spinocerebellar ataxia 3 mice","volume":"94","author":"McLoughlin","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2024.07.008_bb0445","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.nbd.2013.04.019","article-title":"Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon","volume":"58","author":"Evers","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.molmed.2024.07.008_bb0450","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.omtn.2017.06.019","article-title":"Antisense oligonucleotide-mediated removal of the polyglutamine repeat in spinocerebellar ataxia type 3 mice","volume":"8","author":"Toonen","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.molmed.2024.07.008_bb0455","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12311-020-01179-7","article-title":"Antisense oligonucleotide therapy targeted against ATXN3 improves potassium channel-mediated Purkinje neuron dysfunction in spinocerebellar ataxia type 3","volume":"20","author":"Bushart","year":"2021","journal-title":"Cerebellum"},{"key":"10.1016\/j.molmed.2024.07.008_bb0460","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123193","article-title":"Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles","volume":"3","author":"Friedrich","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.molmed.2024.07.008_bb0465","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.omtn.2017.04.005","article-title":"Evaluation of antisense oligonucleotides targeting ATXN3 in SCA3 mouse models","volume":"7","author":"Moore","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.molmed.2024.07.008_bb0470","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.omtn.2020.07.030","article-title":"Antisense oligonucleotide therapeutic approach for suppression of ataxin-1 expression: a safety assessment","volume":"21","author":"O\u2019Callaghan","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.molmed.2024.07.008_bb0475","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.bbrc.2007.08.062","article-title":"Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination","volume":"362","author":"Schmitt","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.molmed.2024.07.008_bb0480","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2024.07.008_bb0485","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2024.07.008_bb0490","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","article-title":"Antisense oligonucleotide therapies for neurodegenerative diseases","volume":"42","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.molmed.2024.07.008_bb0495","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1124\/jpet.113.212407","article-title":"Pharmacology of a central nervous system delivered 2\u2032-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates","volume":"350","author":"Rigo","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.molmed.2024.07.008_bb0500","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1250276","article-title":"Nucleic acid-based therapeutics for the treatment of central nervous system disorders","volume":"14","author":"McCartan","year":"2023","journal-title":"Front. Genet."},{"key":"10.1016\/j.molmed.2024.07.008_bb0505","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2024.07.008_bb0510","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.neurol.2024.03.003","article-title":"Gene editing as a therapeutic strategy for spinocerebellar ataxia type-3","volume":"180","author":"Deglon","year":"2024","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.molmed.2024.07.008_bb0515","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.conb.2021.11.001","article-title":"RAN proteins in neurodegenerative disease: Repeating themes and unifying therapeutic strategies","volume":"72","author":"Guo","year":"2022","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.molmed.2024.07.008_bb0520","doi-asserted-by":"crossref","first-page":"18591","DOI":"10.1073\/pnas.2005748117","article-title":"Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS\/FTD mice","volume":"117","author":"Zu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2024.07.008_bb0525","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3390\/ijms21010216","article-title":"Disrupted calcium signaling in animal models of human spinocerebellar ataxia (SCA)","volume":"21","author":"Prestori","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2024.07.008_bb0530","doi-asserted-by":"crossref","DOI":"10.1358\/dof.2009.34.12.1443434","article-title":"Therapeutic prospects for spinocerebellar ataxia type 2 and 3","volume":"34","author":"Bezprozvanny","year":"2009","journal-title":"Drugs Future"},{"key":"10.1016\/j.molmed.2024.07.008_bb0535","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neulet.2018.02.005","article-title":"Ion channel dysfunction in cerebellar ataxia","volume":"688","author":"Bushart","year":"2019","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.molmed.2024.07.008_bb0540","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198040","article-title":"Dendritic potassium channel dysfunction may contribute to dendrite degeneration in spinocerebellar ataxia type 1","volume":"13","author":"Chopra","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2024.07.008_bb0545","doi-asserted-by":"crossref","first-page":"7405","DOI":"10.3390\/ijms24087405","article-title":"Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to Therapeutics","volume":"24","author":"Paulino","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2024.07.008_bb0550","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41582-018-0051-6","article-title":"Spinocerebellar ataxias: prospects and challenges for therapy development","volume":"14","author":"Ashizawa","year":"2018","journal-title":"Nat. Rev. Neurol."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491424001941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491424001941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T15:47:04Z","timestamp":1739375224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491424001941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":110,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1471491424001941"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2024.07.008","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging therapies in hereditary ataxias","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2024.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}